



CORRIGENDUM

Corrigendum

Sailasuta N, Harris K, Tran T, Ross B. Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study. *Neuropsychiatr Dis Treat*. 2011;7:495–499.

Abstract: The third sentence should be 'Calculation of the initial slope was similar in a single subject, examined twice, 4 months apart (test–retest 8%).'

Methods, 'Patients' section: The second line should be 'A total of 24 MRI/MRS studies were performed on five

subjects of whom one had AD, two had mild cognitive impairment (MCI) and two were healthy older adults with mean age of 78 ± 3 years, and two were females. The AD subject was examined twice.'

Methods, 'Neuroimaging and Spectroscopy' section: The following sentence should be added to the end, 'Test–retest of ^{13}C MRS in an AD was performed at 4 months with reproducibility of 8%.'

Table 1 has been revised, as shown below.

Table 1 Compilations of subjects' characteristics, proton, carbon MRS, and neuropsychological assessment results

	Patient 1 control	Patient 2 control	Patient 3 MCI	Patient 4 MCI	Patient 5A* AD	Patient 5B* AD
Subject characteristics						
Age	80	83	77	81	76	
Gender	M	M	M	M	F	
MMSE	30	28	26	27	22	
Proton MRS results						
NAA/Cr	1.45	1.37	1.47	1.37	1.62	1.39
mi/Cr	0.56	0.72	0.77	0.74	0.85	0.83
NAA/mi	2.6	1.92	1.92	1.85	1.34	1.67
Carbon MRS results						
Rate of bicarbonate production (% FE/minute)	0.023	0.03	0.042	0.033	0.056	0.06
Neuropsychological assessment (Z scores)						
Attention/concentration	WNL	WNL	-2	WNL	-1.6	-1.6
Working memory						
Psychomotor/Information processing	WNL	WNL	WNL	WNL	-1.5	-1.5
Language functions	WNL	WNL	-1.5	WNL	-1.5	-1.5
Verbal memory	WNL	WNL	-1.3	-1.3	-3	-3
Nonverbal memory	WNL	WNL	-3	WNL	-3	-3
Visuospatial/construction	WNL	-1.4	-1.4	-2	-2	-2
Executive functions	WNL	-1.4	-2.5	WNL	-3	-3
Motor functions	WNL	WNL	-1.3	WNL	WNL	WNL

Notes: *The AD subject was examined twice with a 4-month interval between studies.

Abbreviations: AD, Alzheimer's disease; Cr, creatine; FE, fractional enrichment; mi, myo-inositol; MCI, mild cognitive impairment; MMSE, mini-mental state examination; MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate; WNL, within normal limits.

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.